Meiri H, Kugler N, Svirsky R, Kagan O, Brown RN, et al. (2020) Pre-Twin Screen - A Multi- Disciplinary Approach for a Personalized Prenatal Diagnostics and Care for Twin Pregnancies. Int J Womens Health Wellness 6:110. doi.org/10.23937/2474-1353/1510110

RESEARCH ARTICLE | OPEN ACCESS DOI: 10.23937/2474-1353/1510110

Pre-Twin Screen - A Multi-Disciplinary Approach for a Personalized Prenatal Diagnostics and Care for Twin Pregnancies

Hamutal Meiri1,2*, Nadav Kugler1, Ran Svirsky1,2, Oliver Kagan3, Richard Nicolas Brown4, Piere Miron4, Antoni Borrell5, Anna Goncé5, Mar Bennasar5, Annegret Geipel6, Brigitte Strizek6, Argyro Syngeleki7, Kypros Nicolaides7, Howard Cuckle2 and Ron Maymon1,2

1Department of Obstetrics and Gynecology, Yitzhak Shamir University, Israel

2Department of Obstetrics and Gynecology, Tel Aviv University, Israel

3Faculty of Medicine, University of Tubingen, Germany

4Department of Obstetrics & Gynaecology, McGill University, Canada

5Hospital Clinic Barcelona, Consorci Institut d'Investigacions Biomèdiques August Pi iSunyer (IDIBAPS), Spain

6Division of Prenatal Medicine, University Hospital Bonn, Germany

7The Fetal Medicine Institute, King's College Hospital, UK


The prevalence of twin pregnancies is rising globally due to increased assisted conception and advanced maternal age in pregnancy. Twin pregnancies have 5-9 times higher frequencies of fetal chromosomal and structural abnormalities, often deliver preterm, and have high prevalence of gestational diabetes mellitus (GDM), preeclampsia (PE), and intrauterine growth restriction (IUGR) compared to singletons. Twins have special complications such as twins-to twin transfusion syndrome in mono chorionic (MC) twins. Consequently, more twins are born prematurely, suffer from low birth weight, cerebral palsy, etc., often requiring admission to newborn intensive care units, and develop motor and cognitive disorders for life. These impose a huge burden on individuals, families, and the society.

The Pre-Twin Screen project aim to develop a multi-marker, personalized, prenatal diagnostics model to predict feto-maternal complications in twins. A multi-national network will recruit a statistically powered cohort of 1,200 twins and follow them through pregnancy up to delivery utilizing prior risk, biochemical, endocrine, imagine, immunology and cell free DNA (cfDNA) measures. Initial twin cohorts (Prof. Maymon, Israel), revealed good prediction of Down syndrome, PE, and GDM by prior risk, ultrasound and serum markers. We will test all the above, add cfDNA and evaluate structural and chromosomal abnormalities developed by Prof. Kagan (Tubingen, Germany), imagine standardised by Prof.'s Brown and Miron (McGill, Canada) for MC twins, and endocrine, sonographic, and biophysical markers of Prof. Borrell (Barcelona, Spain), and of Dr. Geipel (Bonn, Germany). Prof. Nicolaides (London, UK) will contribute his large twin cohort data. Prof. Cuckle (Israel) will conduct modelling with our large depository to yield risk stratification algorithms for twins, offering personalized, preventive clinical care of feto-maternal disorders. This would enable a paradigm shift in prenatal personalized care for twin pregnancy.


Twin pregnancy, Mono-chorionic twin, Di-chorionic twins, TTTS, Placenta accrete, Vasa previa, Preeclampsia, IUGR, GDM, Preterm delivery, Biomarkers, NIPT, Ultrasound, Doppler


Twins account for 3-4% of all births and over the last two decades the rate of twin pregnancies has increased steadily worldwide essentially due to a widespread conception by in vitro fertilization and use of ovulation drugs, and the increased age of women when they conceive [1]. Twins are substantially at higher risk than singletons for all common feto-maternal pregnancy complications. For example, in twin pregnancies, the rate of preeclampsia (PE), is about 10%, which is 3-times higher than in singletons [2,3]. While in singleton the average gestational age (GA) at delivery is 39 weeks (wks), mean GA for twin delivery is 36 wks [4,5], which is considered preterm, reflecting a 9-times higher prevalence of spontaneous preterm birth (sPTD) compared to singletons [6,7].

Gestational diabetes mellitus (GDM) is accounting for ~ 22% of twin pregnancies compared to 7-11% in singletons [8]. Twins, compared with singletons, have higher rates of stillbirth, neonatal and infant mortality, low birth weight, chromosomal or structural defects [9], and various developmental disorders [1]. In addition, certain pregnancy complications are specific to mono-chorionic (MC) twins, of which the most common is twin-to-twin transfusion syndrome (TTTS), an anastomosis of blood vessels formed between the twins' pregnancy vascular system due to their close proximity, which is associated with death or severe disabilities of the donor or the recipient twin or both [10-12].

The Challenge

Despite the increased risk for pregnancy complications, twins are excluded from almost all major prenatal clinical studies. As a result -the identification and prevention offeto-maternal complications in twins are lagging behind risk prediction, prevention and management of singletons [13,14].

Our working hypothesis is that utilizing a personalized prenatal approach for a multi-marker risk stratification in twin pregnancy we could decrease mortality and morbidity of both pregnant women and of their twin babies. Given the high prevalence of twin pregnancy conceived through the challenges (cost and health) of assisted reproduction [15], the approach will not only save maternal and new-borns life and reduce complications, but it will also be a huge assistance to cost saving and to efficient use of the limited healthcare resources.

Risk prediction tools will enable to identify patients who may be helped by: 1) The use of low dose aspirin to prevent PE [16], prevention of GDM by life style changes, diet and drugs [17], reduce sPTD with vaginal progesterone or placing a pessary or both [18,19], or save fetallife by laser surgery in cases of TTTS [20].

We offer a multi-disciplinary experienced team to embark on the challenge to offer personalized and predictive feto-maternal evaluation starting early in pregnancy and continuing to delivery to enable prevention and treatment.

Pre-Twin Screen

This is an international collaboration among world-renowned centres specializing in twin pregnancy care. Our team has led pioneering but small-scale twin perinatology studies that were already published in prestigious journals. These paved the way to embark on the Pre-Twin Screen project for combining all the approaches and generate a big data collection for the deciphering of individual risk for the personalised prenatal diagnosis and management of twin pregnancies at a global level. We hope to generate the "Gold Standard" for twin pregnancy management.

Many aspects contribute to the special needs of twins for prenatal personalized medicine as specified in the background. Twins have a 3-9 times higher prevalence of major feto-maternal complications (PTD, PE, IUGR, GDM), frequently ends with low birth weight, cerebral palsy, long stay in NICU, and the lifelong complications that generate heavy economic and emotional burden for individuals, families and the society [1-15]. Twin mothers are often at an increased risk for cardiovascular diseases, diabetes and obesity that shorten their life expectancy by at least a decade [1]. MC twins often develop TTTS leading to the death of the donor, recipient or both twins [10-12]. Our preliminary studies generated different marker profiles of twins compared to singletons and have demonstrated a different biomarker temporal diversity compared to singleton [21-23]. Together we will generate a rich profile of twin specific measures for personalized diagnostics that will serve for 1) Implementing better clinical care, and 2) Future twin research.

The world of prenatal risk stratification and prevention of major obstetrics syndromes in singleton pregnancy has made a huge leap jump in the last decade leading to successful prediction of chromosomal aberrations, PE, GDM, sPTD, and for a significance prevention of PE, sPTD, and of fetal loss for TTTS or maternal death from vasa- previa or placenta accrete. However, the introduction of such innovation for twin pregnancy is legging a long way behind.

We develop a multi-disciplinary approach for personal prenatal risk stratification, and prevention of feto-maternal complications in twin pregnancies, based on an integrated effort by a multi-national medical centres network. We combined local ongoing cohorts to gain a powered, multi-national cohort to enable a paradigm shift in twin pregnancy management. Unlike international studies of postnatal and adult twin cohorts [24], our focus is prenatal.

Our combined efforts are derived of current progress and achievement. Prof. Maymon and partners pioneered the development of algorithms derived of combined sonographic and serum markers, patient demographics, pregnancy and medical history to enable the prediction of chromosomal abnormalities [21], PE [22], and GDM [23] in twin pregnancy. In treating MC twins with TTTS - Prof. Nicolaides is a leading partner in the international group that develop ultrasound measures and intra uterine laser surgery procedures to save either both twins (50%) or at least one (75%), followed by establishing standards and teaching methods to disseminate this knowledge [25,26]. Dr. Giepel improved outcome by offering shunting procedures to reduce secondary complications [27]. In hospital management of vasa-previa, the group of Prof. Maymon is leading the convoy in the use of steroids to reduce prematurity and maternal complications, facilitating fetal tissue maturation and time delivery, preventing emergency delivery by caesarean (C) section [28,29] or maternal death in cases of placenta accrete [29,30]. Prof. Kagan conducted studies to identify twin related structural and chromosomal complications [10] and described new methods that have been adopted by many in the world. He and his team have pointed out to the impact of chorionicity and maternal serum markers on Down Syndrome screening in twin pregnancies in the 1st trimester and identified the discordance in nuchal translucency thickness in the prediction of severe TTTS [31]. Prof. Burrell in Spain also identified many genetic complications in twin pregnancies. He has also conducted large studies to investigate measures of fetal growth in twins [32] to allow close surveillance and time-delivery in cases of IUGR. Prof.'s Brown &Mironin Canada led many sonographic studies showing the impact of IVF on increasing complications in twins, and emphasized the endocrine impact in these cases [33,34].

Taken together, the team adopt all procedures developed by each to create a comprehensive innovative approach with the aim to yield an unprecedented multiple dimensions and systematic way for identification of feto-maternal pregnancy complications in twin, thus offering risk stratification and prediction in twin to enable prevention and treatment, and generate a "gold standard" for broad implementation.


Our working hypothesis is that utilizing a personalized prenatal approach for a multi-marker risk stratification in twin pregnancy, we could decrease mortality and morbidity of both pregnant women and of their twin babies. Given the high prevalence of twin pregnancy conceived through the challenges (cost and health) of assisted reproduction [1,15] the approach will not only save maternal and new born life and reduce complications, but it will also be a huge assistance to cost saving and to efficient use of the limited healthcare resources.

Risk prediction tools will enable: 1) PE prevention by low dose aspirin [16], prohibit GDM by life style changes, diet and drugs [17], reduce sPTD with vaginal progesterone or placing a pessary or both [18,19], or save fetal life by laser surgery in cases of TTTS [20]. We leverage on having a multi-disciplinary experienced team as outlined above.

Our Specific Objectives

1. Build a large multi-centre computerized registry of twin pregnancy with a longitudinal data set of the entire pregnancy to determine the base line for unaffected pregnancies compared to feto-maternal complications.

2. Conduct a longitudinal assessment of imaging (chorionicity, placental location, Vasa Previa, TTTS, Doppler blood flow to internal fetal organs including Ductus Venousus, testing of biochemical markers (PAPP-A, PlGF, PP13, Inhibin A, HCG), perform biophysical measures (mean arterial blood pressure (MAP), UTPI), and evaluate immunological markers of white blood cells (mainly natural killer cell (NK cells). Accordingly, using the prospective cohort of all partners we will determine the differences in markers levels for each of the biophysical, biochemical, molecular, and immunological markers that will be standardized (adjusted to MoM) to compare normal outcomes to different pregnancy complications.

3. Assess the major structural and chromosomal defects by anomaly scan, NIPT, NT, chromosomal microarrays, and analysis of carriers of single gene mutations and their progeny.

4. Decipher the contribution of endocrinology and imagine markers regulating fetal growth including blood flow to essential organs, and endocrine markers (such as adiponectin, leptin, PYY, TNF alpha, IL6, etc.), strengthen them with metabolic measures (sugars, LDL, HDL, triglyceride, lipoprotein, and haemoglobin A1C) standardly tested in pregnancy, and combine the entire repertoire to improve accuracy of personalized predicted complications.

5. Develop a differential diagnosis and prediction model(s) from all the above to yield a powerful, multi-disciplinary and personally guided analytical tools for prenatal risk prediction of feto-maternal complications including the evaluation of impact of gender, which appears to affect the severity of the complications [34].

6. Generate a cost-effective economic model for the prediction of pregnancy complications in twin pregnancies.

7. Create a comprehensive mathematical and epidemiological model for a personalized prenatal diagnosis for guiding RCTs for the prevention of twin pregnancy complications with drugs, surveillance, and in utero laser surgery, thus saving fetal and maternal life.

We aim to offer prediction of PE, low birth-weight, sPTD, - GDM and structural and chromosomal abnormalities for future prevention including the reduction of cerebral palsy. The anticipated twin registry and sample bank, and the multi-marker -based analysis and prediction will integrate patients of different origin, thus enabling model refining for many countries and nations. If successful, our study will turn into a paradigm shift of clinical services for twin pregnancies. Thus, when the results will become available, we will proactively cooperate with patients organizations such as the European Foundation for the Care of Newborn Infants (EFCNI) (http://www.efcni.org/ or the Twins and multiple birth association (https://www.tamba.org.uk/) and cooperative act as the advocacy group to turn our project achievement to clinical practice. In addition, evaluating twin pregnancy our way will path the way for multi-center, randomized drug control (RCTs) studies for prevent in pregnancy complications in twins.

We are approaching the individual local ethics committee to obtain the IRB approvalsand upgrade marker measurements, assure training and proper testing. It involves standardized history collection, and verified testing for biochemical, biophysical, imagine, endocrine and immunological measures including cell free DNA (cfDNA). Our pilot will involve algorithms build up on part of the population (approximately 300 twin pregnancies). This will be subsequently validated for the entire cohort. We aim to follow, when appropriate the competing risk model adjusted to twins to enable risk stratification. There is also a plan to generate cost benefit evaluation. At the project ends we aim to turn our achievement into the standards of clinical care for twin pregnancy and introduce differential management for twin pregnancy complications. This will be based on using: (1) Sonography for TTTS, vasa Previa, placenta Accrete, etc. to enable close surveillance or surgery intervention, or (2) Using risk stratification to refer patients to RCT studies to prevent PE, GDM, or sPTD. The Future Care we anticipate is shown in (Figure 1).

Figure 1: The stage wise risk stratification for Twin pregnancy.
The three-stage model suggests that all twins undergo first stage screening by history, biophysical markers, imaging (chorionicity, nucal translucency, uterine artery Doppler pulsatility Index (UTPI), cervical length, etc.) and biochemical and hormonal markers. Selected proportion of those considered to be at high risk are directed to special surveillances and prevention (PE by aspirin, GDM by diet/drug treatment, sPTD by progesterone). Low risk patients are directed to regular pregnancy follow to delivery. Intermediate risk undergo second stage evaluation.
At the second evaluation by ultrasound and markers, a selected proportion of those identified then to be at high risk are directed to special surveillances and prevention. These includes TTTS separation by laser surgery, preterm delivery prevention with progesterone or other means, close surveillances by ultrasound, monitoring biomarkers for IUGR, and preventing term PE by metformin or methods to recover the normal balance of pro and anti-angiogenic factors, and to diet or insulin to prevent GDM. Those at low risk are directed to regular pregnancy follow up until delivery.
Those with intermediate risk undergo third stage evaluation by ultrasound and markers. The emphasis is on plans for term-delivery for prevention for IUGR, reducing anti-, pro-angiogenic balance to fight term PE, use cervical length measures and steroids to facilitate fetal maturation in cases of vasa previa and placenta accrete, among others. Those at low risk are directed to regular pregnancy follow up until delivery, and those at high risk are directed to close surveillance by ultrasound, blood pressure and urine protein measurements until scheduled for emergency delivery. View Figure 1


There are no current multi-marker algorithms for the differential diagnostics of feto-maternal complications for twin pregnancies. Leveraging on our former achievements with small cohorts, we will extend the results to reach a global proof using the multi-national, multi-centre project to meet the needs and cost implications of treating the increased revalence of complications in twin pregnancies. Our ideas are linked to the gall of the TAMBA consortium and the Barker's theory that the intrauterine life shape adulthood health, and are the origin for the vicious cycle of non-communicated disorders (NCDs) [35,36] that gained evidence from the 1942-1944 Dutch famine twin cohort reflecting adulthood health complications of the prenatal harsh period [37]. This has shown that improved prenatal care for the vulnerable pregnant women population reduces the prevalence of NCDs in adults [38], and the exponentially increased cost it adds to the global healthcare expenditure [39].

Our working hypothesis estimates possible prenatal prediction of twin pregnancy complications combining patients' demographics, pregnancy and medical history with biochemical, structural and chromosomal abnormalities, immunological, transcriptional, biophysical, and imaging markers that can be incorporated into powerful risk prediction algorithms to direct personal prenatal care, and to reduce feto-maternal morbidity and mortality. Measured individual markers are incorporated as multiples of the median (MoM) for standardization. Mathematical models [40,41] are implemented, and surveillance and prevention models will be offered. As will be further described in the methodology - the larger the risk, the earlier will be the GA at delivery, adding to the increase burden of prematurity [42-50].

The approach was proven successful in singleton pregnancy and here we implement it for twins. We hope to introduce new "gold standards" for personalized feto-maternal prenatal care for twin pregnancy.


This paper is conducted under the support of ERA NET PerMed: Personalised Medicine -JTC2019 pilot, Project number: 061. The Foundation has no influence on the content and the design of this project. All partners declare no conflict of interest.


  1. Heino A, Gissler M, Hindori-Mohangoo AD, Blondel B, Klungsøyr K, et al. (2016) Variations in multiple birth rates and impact on perinatal outcomes in europe. PLoS One 11: e0149252.
  2. Francisco C, Wright D, Benkő Z, Syngelaki A, Nicolaides KH (2017) Hidden high rate of preeclampsia in twin compared to singleton pregnancies. Ultrasound Obstet Gynecol 50: 88-92.
  3. Fox NS, Roman AS, Saltzman DH, Hourizadeh T, Hastings J, et al. (2014) Risk factors for preeclampsia in twin pregnancies. Am J Perinatol 31: 163-166.
  4. (2005) Mean Gestational Age, by Plurality-United States, 2005. National Vital Statistics System. 2005 natality file.
  5. Bin Zhang, Zhongqiang Cao, Yiming Zhang, Cong Yao, Chao Xiong, et al. (2016) Birth weight percentiles for twin birth neonates by gestational age in China. Sci Rep 6: 31290.
  6. Conde-Agudelo A, Romero R (2014) Prediction of preterm birth in twin gestations using biophysical and biochemical tests. Am J Obstet Gynecol 211: 583-595.
  7. To MS, Fonseca EB, Molina FS, Cacho AM, Nicolaides KH (2006) Maternal characteristics and cervical length in the prediction of spontaneous early preterm delivery in twins. Am J Obstet Gynecol 194: 1360-1365.
  8. Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, et al. (2012) Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: The hyperglycemia and adverse pregnancy outcome (HAPO) Study. HAPO Study Cooperative Research Group. Diabetes Care 35: 526-528.
  9. Bush MC, Malone FD (2005) Down syndrome screening in twins. Clin Perinatol 32: 373-386.
  10. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH (2008) 1First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: Impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31: 493-502.
  11. Khalil A, Rodgers M, Baschat A, Bhide A, Gratacos E, et al. (2016) ISUOG Practice guidelines: Role of ultrasound in twin pregnancy. Ultrasound Obstet Gynecol 47: 247-263.
  12. Quintero RA, Morales WJ, Allen MH, Bornick PW, Johnson PK, et al. (1999) Staging of twin-twin transfusion syndrome. J Perinatol 19: 550-555.
  13. Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH (2007) Discordance in nuchal translucency thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 29: 527-532.
  14. Peeva G, Chaveeva P, Gil Guevara E, Akolekar R, Nicolaides KH (2016) Endoscopic placental laser coagulation in dichorionic and monochorionic triplet pregnancies. Fetal Diagnosis and Therapy 40: 174-180.
  15. Talya Shaulov, Serge Belisle, Michael H Dahan (2015) Public health implications of a north american publicly funded in vitro fertilization program; lessons to learn. J Assist Reprod Genet 32: 1385-1393.
  16. Euser AG, Metz TD, Allshouse AA, Heyborne KD (2016) Low-dose aspirin for pre-eclampsia prevention in twins with elevated human chorionic gonadotropin. J Perinatol 36: 601-605.
  17. Tieu J, Shepherd E, Middleton P, Crowther CA (2017) Dietary advice interventions in pregnancy for preventing gestational diabetes mellitus. Cochrane Database Syst Rev 1: CD006674.
  18. Rodó C, Arévalo S, Lewi L, Couck I, Hollwitz B, et al. (2017) Arabin cervical pessary for prevention of preterm birth in cases of twin-to-twin transfusion syndrome treated by fetoscopic LASER coagulation: The PECEP LASER randomised controlled trial. BMC Pregnancy Childbirth 17: 256.
  19. Norman JE, Norrie J, Maclennan G, Cooper D, Whyte S, et al. (2018) Open randomised trial of the (Arabin) pessary to prevent preterm birth in twin pregnancy with health economics and acceptability: STOPPIT-2-a study protocol. BMJ Open 8: e026430.
  20. Sago H, Ishii K, Sugibayashi R, Ozawa K, Sumie M, et al. (2018) Fetoscopic laser photocoagulation for twin-twin transfusion syndrome. J Obstet Gynaecol Res 44: 831-839.
  21. Ben-Ami I, Maymon R, Svirsky R, Cuckle H, Jauniaux E (2013) Down syndrome screening in assisted conception twins: an iatrogenic medical challenge. Obstet Gynecol Surv 68: 764-773.
  22. Maymon R, Trahtenherts A, Svirsky R, Melcer Y, Madar-Shapiro L (2017) Developing a new algorithm for first and second trimester preeclampsia screening in twin pregnancies. Hypertens Pregnancy 36: 108-115.
  23. Ron Maymon, Hamutal Meiri, Ran Svirski, Eran Weiner, Howard Cuckle (2018) Maternal serum screening marker levels in twin pregnancies affected by gestational diabetes. Arch Gynecol Obstet 299: 655-663.
  24. Duncan GE, Avery A, Hurvitz PM, Moudon AV, Tsang S, et al. (2019) Cohort Profile: TWINS study of environment, lifestyle behaviours and health. Int J Epidemiol 48: 1041-1041h.
  25. Perry H, Duffy JMN, Reed K, Baschat A, Deprest J, et al. (2019) Core outcome set for research studies evaluating treatments for twin-twin transfusion syndrome. Ultrasound Obstet Gynecol 54: 255-261.
  26. Abel JS, Flöck A, Berg C, Gembruch U, Geipel A (2016) Expectant management versus multifetal pregnancy reduction in higher order multiple pregnancies containing a monochorionic pair and a review of the literature. Arch Gynecol Obstet 294: 1167-1173.
  27. Fishel Bartal M, Sibai BM, Ilan H, Katz S, Schushan Eisen I, et al. (2019) Prenatal Diagnosis of Vasa Previa: Outpatient versus Inpatient Management. Am J Perinatol 36: 422-427.
  28. Melcer Y, Jauniaux E, Maymon S, Tsviban A, Pekar-Zlotin M, et al. (2018) Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa. Am J Obstet Gynecol 218: 443.
  29. Sivan E, Spira M, Achiron R, Rimon U, Golan G, et al. (2010) Prophylactic pelvic artery catheterization and embolization in women with placenta accreta: Can it prevent cesarean hysterectomy? Am J Perinatol 27: 455-461.
  30. Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH (2007) Discordance in nuchal translucency thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 29: 527-532.
  31. Ben-Ami I, Molina FS, Battino S, Daniel-Spiegel E, Melcer Y, et al. (2016) Monochorionic diamniotic in vitro fertilization twins have a decreased incidence of twin-to-twin transfusion syndrome. Fertil Steril 105: 729-733.
  32. Borell A (2018) A new comprehensive paradigm for prenatal diagnosis: Seeing the forest through the trees. Ultrasound Obstet Gynecol 52: 563-568.
  33. Brown RN, Mallozzi A, Valenti D (2013) Bidirectional asynchronous arterial flow in monochorionic twins--a precursor to the twin reverse arterial perfusion sequence. Acta Obstet Gynecol Scand 92: 364-365.
  34. Brown RN (2016) Maternal adaptation to pregnancy is at least in part influenced by fetal gender. BJOG 123: 1096.
  35. Campaigning for better outcomes in twin, triplet and higher order pregnancies Campaigns for Twins and Multiples-TAMBA.
  36. Barker DJ (2007) The origins of the developmental of origin theory. J Intern Med 261: 412-417.
  37. (2013) Global action plan for the prevention and control of non-communicable diseases 2013-2020. World Health Organization.
  38. Lumey LH, Stein AD, Susser E (2011) Prenatal Famine and Adult Health. Annu Rev Public Health 32: 237-262.
  39. GBD 2015 Risk Factors Collaborators (2016) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 388: 1659-1724.
  40. Wright D, Tan MY, O'Gorman N, Poon LC, Syngelaki A, et al. (2019) Predictive performance of the competing risk model in screening for preeclampsia. Am J Obstet Gynecol 220: 199.e1-199.e13.
  41. Francisco C, Wright D, Benkő Z, Syngelaki A, Nicolaides KH (2017) Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol 50: 589-595.
  42. Wagner P, Sonek J, Mayr S, Abele H, Goelz R, et al. (2017) Outcome of dichorionic diamniotic twin pregnancies with spontaneous PPROM before 24 weeks' gestation. J Matern Fetal Neonatal Med 30: 1750-1754.
  43. Cheong-See F, Schuit E, Arroyo-Manzano D, Khalil A, Barrett J, et al. (2016) Prospective risk of stillbirth and neonatal complications in twin pregnancies: Systematic review and meta-analysis. BMJ 6.
  44. Gielchinsky Y, Valsky DV, Yanai N, Abdeljawad FJ, Muhaisen MA, et al. (2018) Advances in fetal therapy in complicated monochorionic pregnancies and in severe congenital diaphragmatic hernia: Five years' experience. Harefuah 157: 170-174.
  45. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, et al. (2019) The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynecol Obstet 145: 1-33.
  46. Ben-Ami I, Daniel-Spiegel E, Battino S, Melcer Y, Floeck A, et al. (2015) The association of crown-rump length discrepancy with birthweight discordance in spontaneous versus IVF monochorionic twins: A multicenter study. Prenat Diagn 35: 864-869.
  47. Sabria J, Guirado L, Miró I, Gómez-Roig MD, Borrell A (2017) Crown-rump length audit plots with the use of operator-specific PAPP-A and β-hCG median MoM. Prenat Diagn 37: 229-234.
  48. Borrell A, Grande M, Meler E, Sabrià J, Mazarico E, et al. (2017) Genomic Microarray in Fetuses with Early Growth Restriction: A Multicenter Study. Fetal Diagn Ther 42: 174-180.
  49. Hoopmann M, Kagan KO, Yazdi B, Grischke EM, Abele H (2011) Prediction of birth weight discordance in twin pregnancies by second- and third- trimester ultrasound. Fetal Diagn Ther 30: 29-34.
  50. Yagel S (2009) The developmental role of natural killer cells at the fetal-maternal interface. Am J Obstet Gynecol 201: 344-350.


Meiri H, Kugler N, Svirsky R, Kagan O, Brown RN, et al. (2020) Pre-Twin Screen - A Multi- Disciplinary Approach for a Personalized Prenatal Diagnostics and Care for Twin Pregnancies. Int J Womens Health Wellness 6:110. doi.org/10.23937/2474-1353/1510110